An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead

被引:9
|
作者
Valipour, Mehdi [2 ]
Irannejad, Hamid [1 ]
Keyvani, Hossein [3 ]
机构
[1] Mazandaran Univ Med Sci, Fac Pharm, Dept Med Chem, Sari 4815733971, Iran
[2] Iran Univ Med Sci, Razi Drug Res Ctr, Tehran 1134845764, Iran
[3] Iran Univ Med Sci, Sch Med, Dept Virol, Tehran 1134845764, Iran
关键词
Coronavirus pandemics; SARS-CoV-2; anti-COVID-19drugs; monoclonal antibodies; small molecules; POPULATION-GENETICS; POTENTIAL TREATMENT; SARS-COV-2; BARICITINIB; INHIBITORS; EVOLUTION;
D O I
10.1021/acsptsci.3c00121
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The appearance of several coronavirus pandemics/epidemicsduringthe last two decades (SARS-CoV-1 in 2002, MERS-CoV in 2012, and SARS-CoV-2in 2019) indicates that humanity will face increasing challenges fromcoronaviruses in the future. The emergence of new strains with similartransmission characteristics as SARS-CoV-2 and mortality rates similarto SARS-CoV-1 (& SIM;10% mortality) or MERS-CoV (& SIM;35% mortality)in the future is a terrifying possibility. Therefore, getting enoughpreparations to face such risks is an inevitable necessity. The presentstudy aims to review the drug achievements and challenges in the fightagainst SARS-CoV-2 with a combined perspective derived from pharmacology,pharmacotherapy, and medicinal chemistry insights. Appreciating allthe efforts made during the past few years, there is strong evidencethat the desired results have not yet been achieved and research inthis area should still be pursued seriously. By expressing some pessimisticpossibilities and concluding that the drug discovery and pharmacotherapyof COVID-19 have not been successful so far, this short essay triesto draw the attention of responsible authorities to be more preparedagainst future coronavirus epidemics/pandemics.
引用
收藏
页码:1248 / 1265
页数:18
相关论文
共 50 条
  • [31] DARPins stack up as anti-COVID-19 agents
    Nature Biotechnology, 2020, 38 : 1369 - 1369
  • [32] Anti-COVID-19 measurements for hidradenitis suppurativa patients
    Chandran, Nisha Suyien
    Lee, Ji Hae
    Kurokawa, Ichiro
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 23 - 26
  • [33] Molecular insights to the anti-COVID-19 potential of α-, β- and γ-cyclodextrins
    Kumar, Vipul
    Meidinna, Hazna Noor
    Kaul, Sunil C.
    Gupta, Dharmender
    Ishida, Yoshiyuki
    Terao, Keiji
    Vrati, Sudhanshu
    Sundar, Durai
    Wadhwa, Renu
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2025, 43 (06): : 2890 - 2900
  • [34] CNS penetration of potential anti-COVID-19 drugs
    Richardson, Peter J.
    Ottaviani, Silvia
    Prelle, Alessandro
    Stebbing, Justin
    Casalini, Giacomo
    Corbellino, Mario
    JOURNAL OF NEUROLOGY, 2020, 267 (07) : 1880 - 1882
  • [35] Acute myocarditis associated with anti-COVID-19 vaccination
    Nevet, Alon
    CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, 2021, 10 (02) : 196 - 197
  • [36] Effect of anti-COVID-19 drugs on patients with cancer
    Huang, Weicai
    Liu, Wenyu
    Yu, Tingting
    Zhang, Zhaoyang
    Zhai, Lingyun
    Huang, Panpan
    Lu, Yao
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 268
  • [37] Myositis Associated with the Anti-COVID-19 Covishield Vaccine
    Miqdadi, Amal
    Benmansour, Nouhad
    Herrag, Mohammed
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2023, 19 (01) : 77 - 78
  • [38] DARPins stack up as anti-COVID-19 agents
    Waltz, Emily
    NATURE BIOTECHNOLOGY, 2020, 38 (12) : 1369 - 1369
  • [39] An immunologist's perspective on anti-COVID-19 vaccines
    Milota, Tomas
    Strizova, Zuzana
    Smetanova, Jitka
    Sediva, Anna
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 21 (06) : 545 - 552
  • [40] Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions
    Lin, Min
    Dong, Hai-Yan
    Xie, Huan-Zhang
    Li, Yu-Mei
    Jia, Lee
    DRUG DISCOVERY TODAY, 2021, 26 (03) : 631 - 636